About this trial
This study focuses on individuals with primary hypertension, with the main objective of investigating the effectiveness and safety of high-intensity transcranial alternating current stimulation (Hi-tACS) as a non-invasive, non-pharmacological treatment for hypertension
Eligibility criteria
Qualifiers
Clinical diagnosis of primary hypertension (Grade 1-3) as defined by the Chinese Hypertension Guidelines (Revised Edition 2024).
For females of childbearing potential, agreement to use contraception during the study.
Willing and able to comply with study procedures and provide written informed consent.
Disqualifiers
Women who are pregnant, breastfeeding, or planning pregnancy during the study period.
Resistant hypertension (blood pressure uncontrolled despite adherence to ≥3 antihypertensive drugs of different classes at optimal doses, including a diuretic ), or known secondary hypertension.
History of severe cardiovascular or cerebrovascular disease (e.g., myocardial infarction, stroke, heart failure NYHA Class III-IV) within the past 6 months, or severe hepatic or renal dysfunction (defined as ALT/AST >3× upper limit of normal [ULN], or eGFR <30 mL/min/1.73 m²).
Uncontrolled sleep apnea syndrome, active infectious diseases, chronic wasting diseases, or significant cognitive impairment.
Trial design
Treatments tested in this trial
- Active High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS)
- Sham High-Intensity Transcranial Alternating Current Stimulation (Hi-tACS)